[Comment] Has the limit been reached in treatment of unresectable oesophageal squamous cell carcinoma?

SKYSCRAPER-08, a randomised, double-blind, placebo-controlled, phase 3 trial, marks a milestone in the treatment of oesophageal squamous cell carcinoma.1 Patients were randomly assigned to receive tiragolumab (a TIGIT inhibitor) plus atezolizumab (a PD-L1 inhibitor) and chemotherapy (paclitaxel and cisplatin) or to receive placebo and chemotherapy. Median progression-free survival was 6·2 months (95% CI 5·7–7·2) with tiragolumab plus atezolizumab versus 5·4…